Penn’s Abramson Cancer Center and Children’s Hospital of Philadelphia present

CAR-T AND THE RISE OF CELLICON VALLEY

CME/CNE Accredited Activity

Thursday, May 9, 2019 | 1:00 pm to 9:30 pm
Friday, May 10, 2019 | 8:00 am to 5:00 pm

REGISTER AT PENNMEDICINE.ORG/CART2019

Irvine Auditorium and Perelman Quadrangle // 3401/3417 Spruce St., Philadelphia, PA 19104
The University of Pennsylvania Museum of Archaeology and Anthropology // 3260 South St., Philadelphia, PA 19104
CAR-T AND THE RISE OF CELLICON VALLEY

PHILADELPHIA | CME/CNE Accredited Activity

THURSDAY, MAY 9, 2019 — KEYNOTE ADDRESS
FRIDAY, MAY 10, 2019 — PRESENTATIONS:

CURRENT APPLICATION OF CAR T CELLS
Moderator: David L Porter, MD // Penn Medicine
Carl H June, MD // Penn Medicine
David Maloney, MD, PhD // Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance/University of Washington
James N Kochenderfer, MD // National Cancer Institute

TOXICITY MANAGEMENT
Moderator: Stephan A Grupp, MD, PhD // Children’s Hospital of Philadelphia
Shannon L Maude, MD, PhD // Children’s Hospital of Philadelphia
Sattva S Neelapu, MD // The University of Texas MD Anderson Cancer Center
Renier J Brentjens, MD, PhD // Memorial Sloan Kettering Cancer Center

OVERCOMING RESISTANCE/NOVEL CAR STRATEGIES
Moderator: Carl H June, MD // Penn Medicine
Megan S Lim, MD, PhD // Penn Medicine
Travis Young, PhD // California Institute for Biomedical Research
Martin Pule, MB BCh, MRCP // University College London

GENE DELIVERY AND EDITING FOR BETTER CARS
Moderator: Michael C Milone, MD, PhD // Penn Medicine
Alexander Marson, MD, PhD // University of California, San Francisco
Bruce McCreedy, PhD // Precision Biosciences
David J Rawlings, MD // Seattle Children’s Research Institute

NEW TARGETS AND TECHNOLOGIES
ALLOGENEIC AND TREG CAR Ts
Moderator: Marco Ruella, MD // Penn Medicine
Christine Brown, PhD // City of Hope
Carl H June, MD // Penn Medicine
Darrell J Irvine, PhD // Massachusetts Institute of Technology

ALLOGENEIC CAR Ts AND NKs:
THE FUTURE IS NOW?
Moderator: Stephen J Schuster, MD // Penn Medicine
Katy Rezvani, MD, PhD // The University of Texas MD Anderson Cancer Center
David Chang MD, PhD // Allogene Therapeutics
David Gilham, PhD // Celyad

GLOBALIZATION OF CAR T CELL THERAPIES
Moderator: Usman “Oz” Azam, MD // Tmunity
Panel To Be Announced

Plus 10 Breakout sessions. Topics include: cell manufacturing; gene therapy and regulatory considerations; unconventional CARs; cell manufacturing analytics; financial implications; unconventional CARs; Pediatric - SCT, GVHD, antiviral therapies, CAR T in special populations and gene edited SCT for SS and thalassemia; nursing care of adult and pediatric patients. Arrive early on May 9 and tour Center for Advanced Cellular Therapeutics.
OVERVIEW

CAR T represents a turning point in the history of human medicine, a genuine revolution in our approach to disease within the field of cellular therapy and transplant. The recent approval of chimeric antigen receptor (CAR) T cells offers even patients with highly chemo-refractory hematologic malignancies additional treatment options. World experts in CAR T-cellular therapy and hematopoietic stem cell transplantation (HSCT) have been assembled to discuss the development and implementation of this therapy and to weigh in on current applications, best practices, novel strategies and future developments for CAR T cells.

LEARNING OBJECTIVES

Upon completion of this course, participants should be able to:

• Identify current application of CAR T-cell therapy including: accurate patient selection, manufacture and treatment administration
• Implement guidelines for patient management of toxicities of CAR T-cell therapies including cytokine-release syndrome
• List factors in overcoming resistance with novel CAR strategies
• Describe gene delivery and editing for CARs
• Identify the latest targets and technologies for CARs
• Identify the current status of globalization of CAR T-cell therapies and identify principles in ethics of patient access
• Describe current approaches in treatment and supportive care for hematopoietic stem cell transplantation (HSCT) in pediatric patients with nonmalignant conditions
• Identify the latest evidence based standards in nursing care resulting from the recent advances in cell therapy and transplant

WHO SHOULD ATTEND

These activities are intended for both adult and pediatric hematologist-oncologists, medical oncologists, hematologists, hematopathologists, immunologists, immunobiologists, transfusion medicine, researchers and other healthcare professionals interested in the latest advances in the use of CAR T-cell therapy. Fellows, nurses, nurse practitioners, physician assistants, and other healthcare professionals interested in the treatment of adult and pediatric patients with cellular therapies are also invited to attend.

ACCREDITATION AND DESIGNATION OF CREDIT

ACCREDITATION

In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

DESIGNATION OF CREDIT

PHYSICIANS: Penn Medicine designates this live activity for a maximum of 8.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

NURSES: This program awards 8.25 contact hours.

PHYSICIAN ASSISTANTS: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credits™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 8.25 Category 1 credits for completing this activity.
Penn’s Abramson Cancer Center and Children’s Hospital of Philadelphia present

CAR-T AND THE RISE OF CELLICON VALLEY

A CME/CNE Accredited Activity

Thursday, May 9, 2019  |  1:00 pm to 9:30 pm
Friday, May 10, 2019  |  8:00 am to 5:00 pm

REGISTER AT PennMedicine.org/CART2019